POLYMED - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | POLYMED | Market Cap | 16,113 Cr. | Current Price | 1,590 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 46.2 | Book Value | 285 ₹ | Dividend Yield | 0.22 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,720 ₹ | DMA 200 | 1,956 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.31 % | PAT Qtr | 89.0 Cr. | PAT Prev Qtr | 87.9 Cr. |
| RSI | 44.3 | MACD | -74.7 | Volume | 3,99,988 | Avg Vol 1Wk | 1,57,152 |
| Low price | 1,430 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.49 | Debt to equity | 0.08 |
| 52w Index | 10.6 % | Qtr Profit Var | 2.10 % | EPS | 34.4 ₹ | Industry PE | 33.5 |
📊 Analysis: POLYMED is trading at ₹1,590, below both its 50 DMA (₹1,720) and 200 DMA (₹1,956), indicating short-term weakness. RSI at 44.3 suggests near oversold conditions, while MACD (-74.7) reflects strong bearish momentum. Volume is significantly higher than the weekly average, showing strong intraday participation. Fundamentals remain decent, but technicals point to caution for intraday trades.
💡 Optimal Buy Price: ₹1,575–1,585 (near support zone, risk-managed entry).
🎯 Profit-Taking Levels: ₹1,610–1,625 (first resistance), ₹1,650 (secondary resistance if momentum sustains).
🛡️ Stop-Loss / Loss Protection: ₹1,560 (below intraday support).
⏱️ If Already Holding: Exit near ₹1,610–1,625 if momentum stalls. If price sustains above ₹1,625 with strong volume, hold for ₹1,650. Exit immediately if price breaks below ₹1,560 with heavy selling pressure.
Positive
- EPS at ₹34.4 reflects consistent profitability.
- ROCE (18.2%) and ROE (14.2%) show decent capital efficiency.
- DII holding increased (+0.31%), reflecting domestic institutional support.
- PEG ratio at 1.49 suggests reasonable valuation relative to growth.
- Debt-to-equity ratio at 0.08 indicates low leverage risk.
Limitation
- Stock trading below both 50 DMA and 200 DMA indicates weak trend.
- High P/E of 46.2 compared to industry average of 33.5 suggests overvaluation.
- MACD strongly negative (-74.7), showing bearish undertone.
- Dividend yield at 0.22% offers negligible investor return.
Company Negative News
- FII holding decreased (-0.36%), showing reduced foreign investor confidence.
- Quarterly PAT only marginally improved (₹89 Cr. vs ₹87.9 Cr.), limiting growth momentum.
Company Positive News
- Quarterly profit variation at +2.10% shows slight operational improvement.
- DII holding increased (+0.31%), reflecting domestic institutional support.
Industry
- Industry PE at 33.5, lower than POLYMED’s valuation, suggesting premium pricing.
- Medical devices and healthcare sector remains growth-oriented, supported by rising demand and innovation.
Conclusion
⚖️ POLYMED presents moderate intraday potential with strong volume but weak technicals. Entry near ₹1,575–1,585 with exit around ₹1,610–1,625 is advisable. If momentum sustains, ₹1,650 is achievable. Strict stop-loss at ₹1,560 ensures risk management. Suitable for cautious intraday traders.